Key result
KCNQ1 antibodies abolish arrhythmias in in vitro LQTS2 models via IKs channel agonism.
Why the study?
No targeted therapy for LQTS exists, and a causative relationship between KCNQ1 antibodies and accelerated cardiac repolarization had never been directly demonstrated.
Do KCNQ1 antibodies improve cardiac repolarization and prevent arrhythmias in preclinical models of Long QT Syndrome Type 2?
Population
Chinese hamster ovary cells overexpressing IKs channels and human iPSC-derived cardiomyocytes
Comparison
Purified KCNQ1 antibodies vs baseline or control conditions
Design
Preclinical in vitro electrophysiological study
Authors
Loading...
Supports KCNQ1 antibody research in LQTS2; leaves open clinical translation pending in vivo and human studies.
Do KCNQ1 antibodies improve cardiac repolarization and prevent arrhythmias in preclinical models of Long QT Syndrome Type 2?
KCNQ1 antibodies act as IKs channel agonists and can reverse prolonged repolarization and suppress arrhythmias in preclinical models of LQTS2.
Maguy et al. (2020) studied Long QT Syndrome Type 2. KCNQ1 antibodies was evaluated. KCNQ1 antibodies acted as agonists on IKs channels, reversing prolonged cardiac repolarization and abolishing arrhythmic activities in in vitro models of Long QT Syndrome type 2.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: